B of A Securities Downgrades Silk Road Medical to Underperform, Lowers Price Target to $28
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Travis Steed has downgraded Silk Road Medical (NASDAQ:SILK) from Buy to Underperform and lowered the price target from $51 to $28.
July 12, 2023 | 2:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Silk Road Medical's stock rating has been downgraded from Buy to Underperform by B of A Securities, with a lowered price target from $51 to $28.
The downgrade from Buy to Underperform by a reputable analyst at B of A Securities is a negative signal to investors. The lowered price target from $51 to $28 further indicates a bearish outlook for the stock, which could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100